Log In
Print
BCIQ
Print
Print this Print this
 

OS2966

  Manage Alerts
Collapse Summary General Information
Company OncoSynergy Inc.
DescriptionHumanized mAb against integrin beta (1;CD29)
Molecular Target Integrin beta(1) (CD29)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationBrain cancer
Indication DetailsTreat recurrent glioblastoma multiforme (GBM)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today